Ethos Acquires Dr.Evidence

We’re pleased to announce that Ethos Software has acquired Dr.Evidence. The transaction was completed on December 31, 2025.

Dr.Evidence "Dr.E" is the AI-powered labeling and regulatory landscape intelligence platform designed specifically for biopharma companies. As an Authoritative Source, it helps labeling and regulatory professionals accelerate time-to-market by providing access to more than 100 million documents. This includes drug labels; regulatory approval packages and guidance documents; clinical trials; and scientific literature. Biopharma leaders rely on Dr.Evidence to tackle their most pressing growth and compliance challenges.

Dr.Evidence will operate as a subsidiary of Ethos Software. There will be no fundamental changes to the overall product offering. Indeed, clients can expect expanded capabilities and continued product investment now that Dr.E is part of the Ethos family of companies.